Author

Yijing Li

Observed name: Y. Li

Institution: Jiangsu Hengrui Medicine (China)

Observed institutions: Jiangsu Hengrui Medicine (China), Ascentage Pharma Group Inc. (United States)

ORCID: 0009-0008-0206-5576

Observed ORCID: 0009-0008-0206-5576

OpenAlex ID: A5043518595

Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024 · Yuqin Song, Zhengming Jin, et al. · Clinical Cancer Research · 20

OA12 A Phase I Study of Novel Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced SCLC or Other Solid Tumor

2018 · Y. Wu, N.J. Lakhani, et al. · Journal of Thoracic Oncology · 4

61 | a Pivotal Study of Shr2554, an Oral Inhibitor Against Enhancer of Zeste Homolog 2 (ezh2), in Relapsed or Refractory (r/r) Peripheral T‐cell Lymphoma (ptcl)

2025 · Y. Song, Z. Li, et al. · Hematological Oncology · 1

Supplementary Table S3 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024 · Yuqin Song, Zhengming Jin, et al.

Data from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024 · Yuqin Song, Zhengming Jin, et al.

Supplementary Figure S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024 · Yuqin Song, Zhengming Jin, et al.

Supplementary Table S4 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024 · Yuqin Song, Zhengming Jin, et al.

Supplementary Method 1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024 · Yuqin Song, Zhengming Jin, et al.

Supplementary Table S5 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024 · Yuqin Song, Zhengming Jin, et al.

Supplementary Table S6 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024 · Yuqin Song, Zhengming Jin, et al.

Supplementary Table S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024 · Yuqin Song, Zhengming Jin, et al.

Data from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024 · Yuqin Song, Zhengming Jin, et al.

Supplementary Table S2 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024 · Yuqin Song, Zhengming Jin, et al.

Works count: 13

Citation count: 25

H-index: 2

I10-index: 1